Journal article
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
Bernard Chevalier, Carlo Dimario, Franz-Josef Neumann, Donald E Cutlip, David O Williams, John Ormiston, Eberhard Grube, Robert Whitbourn, Jessie Coe, Lewis B Schwartz, undefined ZOMAXX I Investigators
Catheterization and Cardiovascular Interventions | Published : 2013
DOI: 10.1002/ccd.24958
Abstract
BACKGROUND: The ZOMAXX I trial tested the noninferiority of a zotarolimus-eluting coronary stent (ZoMaxx(™) ) when compared with a paclitaxel-eluting coronary stent (Taxus(™) Express(2™) ) in a randomized trial of percutaneous intervention for de novo coronary artery stenosis. Angiographic analysis at the primary endpoint of 9 months has been reported previously. The purpose of this follow-on analysis was to describe the clinical results of the ZoMaxx and Taxus cohorts of the ZOMAXX I trial after 5 years. METHODS AND RESULTS: In the ZOMAXX I trial, 199 patients received a ZoMaxx stent and 197 patients received a Taxus stent at 29 investigative sites in Europe, Australia, and New Zealand. The..
View full abstract